Search

Your search keyword '"Queirolo P"' showing total 960 results

Search Constraints

Start Over You searched for: Author "Queirolo P" Remove constraint Author: "Queirolo P"
960 results on '"Queirolo P"'

Search Results

201. Basi scientifiche per la definizione di linee-guida in ambito clinico per il Melanoma cutaneo

202. Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.

205. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma

207. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: An open-label, multicentre, safety study

208. CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients

211. Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012

213. Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors.

214. Effectiveness of dabrafenib in the treatment of patients with BRAFV600–mutated metastatic melanoma in a Named Patient Program

215. No detection of methane on Mars from early ExoMars Trace Gas Orbiter observations

216. Copper smelting and converting: past and present Chilean developments

217. NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.

218. Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.

219. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history

224. 3346 BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine

225. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009

226. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009

227. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT)

228. Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: A series of 39 patients treated with palliative intent

229. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma

232. Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls

233. LBA8_PR - Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)

234. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.

235. Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19

240. Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma

241. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

244. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

245. Spatial organization and social dynamics of Geoffroy’s cat in the Brazilian pampas

246. Geographic distribution modeling of the margay (Leopardus wiedii) and jaguarundi (Puma yagouaroundi): a comparative assessment

248. High prevalence of the G101W germline mutation in the CDKN2A (P16INK4A) gene in 62 Italian malignant melanoma families

Catalog

Books, media, physical & digital resources